Navigation Links
Rigel to Present Research Programs at Scientific Conferences
Date:10/16/2007

SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its scientists will be presenting three poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, October 22-26, 2007. They will highlight drug discovery efforts focused on significant cancer targets including Axl receptor tyrosine kinase (Axl), Polo- like kinase 1 (PLK1) and Janus tyrosine kinase 2 (JAK2).

Axl kinase is a novel therapeutic target for solid tumors. Signaling via Axl drives proliferation, migration and invasion of tumor cells. The data to be presented shows that Axl inhibition may suppress tumor growth via multiple mechanisms. Rigel has potent, small molecule, orally bioavailable Axl inhibitors that show activity in reducing tumor growth and invasion in animal models. One of Rigel's collaborators will also present on Axl at the AACR Special Conference on Advances in Breast Cancer Research in San Diego, October 17-20, 2007.

Selective inhibition of PLK1 could be important in cancer treatment. Rigel has discovered a new class of small molecule PLK1 inhibitors using its image-based high content screening capabilities, which were previously used to discover an Aurora Kinase inhibitor that is currently in clinical studies as a potential cancer therapeutic.

Rigel's scientific team will also be presenting a poster at the International Cytokine Society meeting, October 26-30, 2007 in San Francisco, California.

Poster Presentation at AACR's Advances in Breast Cancer Research

Wednesday, October 17th, 8:00-10:00pm

The receptor tyrosine kinase Axl regulates breast carcinoma cell

invasiveness

Session ID: Poster Session A

Abstract Number: 6186

Poster Presentations at the 2007 AACR-NCI-EORTC Meeting

Tuesday, October 23rd, 12:30-2:30pm

Identification of Polo-like kinase 1 inhibitors through phenotype-based

approaches

Session ID: Small Molecule Therapeutic Agents: Kinase Inhibitors

Abstract Number: A234

Wednesday, October 24th, 12:30-2:30pm

Novel small molecule inhibitors of the Axl receptor tyrosine kinase block

tumor growth

Session ID: Small Molecule Therapeutic Agents: Kinase Inhibitors

Abstract Number: B230

Wednesday, October 24th, 12:30-2:30pm

Selective inhibitors of JAK2 kinase as potential therapeutic agents

Session ID: Small Molecule Therapeutic Agents: Kinase Inhibitors

Abstract Number: B235

Poster Presentation at Cytokines 2007 Meeting

Saturday, October 27th, 5:30-7:30pm

A class of small molecules that inhibit TNFa-induced survival and death

pathways via prevention of interactions between TNFaRI, TRADD and RIP1

Session ID: Poster Session 1

Abstract Number: 46

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "goal," "expects," "may" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-Q for the quarter ended June 30, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.430.3777

Email: susan@alchemyemail.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Vermillion, Inc. (NASDAQ: VRML ... today announced the formation of the Steering Committee for ... --> Pelvic masses can present physicians ... management. Once pregnancy is ruled out, pelvic masses may ... advanced endometriosis, benign ovarian tumors and gastrointestinal and urinary ...
(Date:2/11/2016)... 2016  Wellcentive today announced it has been ... -based community care organization (CCO) with more ... quality reporting and care management solutions and services. ... of quality managers, analysts and care managers while ... serving FamilyCare members. Oregon ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
(Date:2/10/2016)... Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announce that Mitsui & Co. Ltd., its partner in ... plant, is investing an additional CDN$25 million in the ... stake from 30% to 40%.  Mitsui will also play ... produced in Sarnia , providing dedicated ...
Breaking Biology Technology:
(Date:1/25/2016)... Pa. , Jan. 25, 2016   Unisys Corporation ... system at John F. Kennedy (JFK) International Airport, New ... Protection (CBP) identify imposters attempting to enter the ... not belong to them. pilot testing of the ... initially at three terminals at JFK during January 2016. --> ...
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):